Zai Lab
Zai Lab's revenue rose 15.3% to $460 million in fiscal 2025. Its operating margin was −49.9%, up from −70.7% a year earlier. Free cash flow was −$159 million. The diluted share count rose 10.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Zai Lab lost money in fiscal 2025: a net loss of $176 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,409 | 1,008 | 806 | 780 | 690 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | −125.2x | −44.0x |
| Current ratio | 7.8x | 8.0x | 4.6x | 3.5x | 2.5x |
| Quick ratio | 7.7x | 7.8x | 4.4x | 3.4x | 2.3x |
Cash flow
Projections
Project Zai Lab's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $65,804 of Zai Lab shares on the open market, and 6 insiders sold $11.1 million, $9.2 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Yajing ChenChief Financial Officer | Sold plan | 260 | $27.00 | $7,020 | Form 4 |
| Aug 12, 2026 | William LisDirector | Sold plan | 8,506 | $25.00 | $212,650 | Form 4 |
| Aug 11, 2026 | Yajing ChenChief Financial Officer | Sold plan | 619 | $25.00 | $15,475 | Form 4 |
| Jul 1, 2026 | Richard GaynorDirector | Bought plan | 1,736 | $19.05 | $33,071 | Form 4 |
| Jun 30, 2026 | Ying DuChairperson & CEO, Director | Sold | 7,026 | $18.53 | $130,192 | Form 4 |
| Jun 26, 2026 | Ying DuChairperson & CEO, Director | Sold | 24,543 | $17.46 | $428,521 | Form 4 |
| Jun 26, 2026 | Frazor Titus Edmondson IIIChief Legal Officer | Sold | 4,103 | $17.46 | $71,638 | Form 4 |
| Jun 26, 2026 | Yajing ChenChief Financial Officer | Sold | 2,264 | $17.46 | $39,529 | Form 4 |
| Jun 22, 2026 | William LisDirector | Sold plan | 7,040 | $18.09 | $127,354 | Form 4 |
| May 18, 2026 | Ying DuChairperson & CEO, Director | Sold plan | 50,000 | $19.00 | $950,000 | Form 4 |
| May 15, 2026 | Ying DuChairperson & CEO, Director | Sold plan | 50,000 | $20.74 | $1.0 million | Form 4 |
| May 14, 2026 | Ying DuChairperson & CEO, Director | Sold plan | 50,000 | $20.09 | $1.0 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −53.0% | −5.7% | −19.2% |
| Altman Z'' | −1.14 | −1.63 | −3.61 |
| Accruals ratio | −12.1% | −3.8% | −2.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Zai Lab side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Zai Lab | FY25 | 15.3% | −49.9% | −34.5% | — | — | — | |
| Travere Therapeutics | FY25 | 110.5% | −12.8% | — | — | — | 7 | Compare |
| BridgeBio Pharma | FY25 | 126.3% | −104.2% | −89.0% | — | — | 3 | Compare |
| Innoviva | FY25 | 14.7% | 39.8% | 47.6% | 17.9% | — | 6 | Compare |
| Ardelyx | FY25 | 22.1% | −10.1% | −10.8% | −36.1% | — | 2 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | 0 | 13 | 49 | 144 | 215 | 267 | 399 | 460 |
| Revenue growth | — | — | — | 9,965.9% | 277.0% | 194.8% | 49.0% | 24.0% | 49.6% | 15.3% |
| Gross profit | — | — | 0 | 9 | 32 | 92 | 141 | 171 | 252 | 270 |
| Research and development | 32 | 39 | 120 | 142 | 223 | 573 | 286 | 266 | 234 | 221 |
| Operating income | −38 | −51 | −142 | −203 | −302 | −700 | −404 | −367 | −282 | −229 |
| Net income | −38 | −50 | −139 | −195 | −269 | −704 | −443 | −335 | −257 | −176 |
| Diluted EPS (US$) | −0.40 | −0.23 | −0.26 | −0.30 | −0.35 | −0.76 | −0.46 | −0.35 | −0.26 | −0.16 |
| Diluted shares (millions) | 94 | 218 | 526 | 644 | 777 | 930 | 958 | 966 | 990 | 1,095 |
| Cash flow | ||||||||||
| Cash from operations | −32 | −32 | −98 | −191 | −216 | −549 | −368 | −198 | −215 | −151 |
| Capital expenditure | 2 | 9 | 10 | 6 | 10 | 18 | 25 | 7 | 6 | 8 |
| Free cash flow | −34 | −41 | −108 | −197 | −226 | −568 | −392 | −205 | −221 | −159 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 5 | 10 | 12 | 20 | 25 | 41 | 61 | 80 | 71 | 66 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 84 | 230 | 263 | 276 | 1,187 | 1,409 | 1,008 | 806 | 780 | 690 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 89 | 250 | 302 | 355 | 1,298 | 1,610 | 1,220 | 1,036 | 1,186 | 1,172 |
| Total liabilities | 6 | 14 | 51 | 60 | 128 | 230 | 174 | 240 | 345 | 457 |
| Shareholders' equity | −52 | 235 | 251 | 295 | 1,169 | 1,380 | 1,046 | 796 | 841 | 716 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | 66.6% | 71.1% | 65.8% | 63.8% | 65.6% | 64.1% | 63.1% | 58.6% |
| Operating margin | — | — | −109,897.7% | −1,564.8% | −616.5% | −485.1% | −188.0% | −137.4% | −70.7% | −49.9% |
| Net margin | — | — | −107,810.1% | −1,502.3% | −549.3% | −488.2% | −206.1% | −125.5% | −64.4% | −38.1% |
| Free cash flow margin | — | — | −83,374.4% | −1,517.5% | −462.0% | −393.3% | −182.4% | −77.0% | −55.3% | −34.5% |
| Rule of 40 (growth + FCF margin) | — | — | — | 8,448.4% | −185.0% | −198.5% | −133.4% | −53.0% | −5.7% | −19.2% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −54.9% | −57.2% | −71.5% | −36.7% | −55.3% | −36.5% | −36.3% | −31.4% | −22.6% |
| Return on assets | — | −29.8% | −50.4% | −59.4% | −32.5% | −48.5% | −31.3% | −29.7% | −23.1% | −14.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |